Characterization of Adaptive Immune Responses to Oropouche Virus (OROV) Infection (OROV-IMM)
Oropouche virus (OROV), a re-emerging South American arbovirus causing dengue-like fever and occasional neurological complications, is expanding its circulation towards more densely populated areas in French Guiana, as evidenced by recent cases near Cayenne in 2026. While animal models indicate that B cell-mediated humoral immunity is critical for viral control, the human antibody response to OROV remains poorly characterized. Despite WHO-led international research efforts, there is currently no vaccine, antiviral treatment, or described human monoclonal antibody against OROV - a major gap that hinders therapeutic and vaccine development. Identifying human neutralizing monoclonal antibodies could offer a promising therapeutic option, particularly for vulnerable populations such as pregnant women.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The goal of this project is to characterize the adaptive immune response to OROV infection during the convalescent phase.
The study is based on three complementary populations: (1) 17 adults with confirmed past OROV infection (2020) who will be recontacted for follow-up sampling; (2) 50 adults recruited prospectively from a village with ∼80% seroprevalence, aiming to include at least 20 seropositive individuals for robust analysis of antigen-specific B and T cell responses; and (3) an exploratory cohort of 1 to 10 newly confirmed OROV cases identified during the study period in the Cayenne region, enrolled during the convalescent phase (≥1 month post-diagnosis) to complement the immunological analyses conducted in the first two populations.
A 20 ml blood sample is collected, along with data collection (mainly health data), at the time of enrollment.
The study involves: (1) confirming past OROV infection by detecting OROV-specific polyclonal antibodies in plasma; and (2) characterizing OROV-specific B and T cell responses. Key methodological steps include: isolation of OROV-specific B cells by flow cytometry followed by single-cell culture and stimulation to generate human monoclonal antibodies; screening of secreted mAbs against OROV antigens combined with VDJ sequencing to characterize immunoglobulin repertoires; and structural characterization of neutralizing mAbs using cryo-electron microscopy and nano-imaging to identify conserved epitopes.
연구 유형
연구 유형
등록 (추정된)
등록
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
The study population lives in French Guiana in 3 different areas (Saül, Trois Sauts, and Cayenne and its surroundings), and eligible individuals (Populations 1 and 3) or those residing in a high-seroprevalence geographic area (Population 2) were identified by the National Reference Center (CNR) for Arboviruses at the Institut Pasteur of French Guiana (IPG) as part of arbovirus virological surveillance in French Guiana.
설명
Inclusion Criteria:
For all:
- Adults (≥18 years old)
- Willingness to participate in the study after explanation and signing of the informed consent form
Study population 1:
- Presenting a laboratory-confirmed OROV infection, defined by a positive real-time RT-PCR and/or positive seroneutralization performed as part of the management of and response to the 2020 OROV epidemic in Saül.
Study population 2:
- Residing in Trois-Sauts for at least 5 years
Study population 3:
- Presenting a laboratory-confirmed OROV infection, defined by a positive real-time RT-PCR and/or positive seroneutralization, identified in the Cayenne area and surrounding localities during the study period, as part of the surveillance activities of the CNR for Arboviruses (IPG).
Exclusion Criteria:
For all:
- Pregnant women.
- Individuals presenting with severe chronic pathologies (notably active cancer, primary or secondary immunodeficiency, immunosuppressive treatment, HIV infection, or autoimmune diseases), according to the information declared by the participants.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: OTHER
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
adults with confirmed past OROV infection (2020) recruited from Saül
|
A 20-ml blood sample |
|
adults recruited from Trois-Sauts with ∼80% seroprevalence
|
A 20-ml blood sample |
|
newly confirmed OROV cases identified during the study period in the Cayenne region
|
A 20-ml blood sample |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Characterization of the adaptive immune response to OROV infection during the convalescent phase.
기간: 12 months
|
OROV-specific polyclonal antibodies will be detected in participants' plasma to confirm prior infection. |
12 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Isolate OROV-specific B cells (recognizing the Gn_Gc antigenic complex) and generate human monoclonal antibodies by single B cell culture.
기간: 12 months
|
Isolation of OROV-specific B cells by flow cytometry, followed by culture and stimulation of single B cells to generate and identify human monoclonal antibodies specific to OROV. |
12 months
|
|
Screening of secreted mAbs using OROV antigens and VDJ sequencing to characterize immunoglobulin repertoires.
기간: 12 months
|
secreted mAbs using OROV antigens and VDJ sequencing will be screened to characterize immunoglobulin repertoires. |
12 months
|
|
Structural characterization of neutralizing mAbs by cryo-EM and nano-imaging to identify conserved epitopes.
기간: 12 months
|
cryo-EM and nano-imaging will be performed on neutralizing mAbs to characterize structurally the mAbs |
12 months
|
공동 작업자 및 조사자
협력자
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 2026-047_OROV-IMM
- 2026-A01467-44 (기타 식별자: ID-RCB)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .